"...loss making growth stocks like bnpl and pbh having been...

"...loss making growth stocks like bnpl and pbh having been crushed nonstop since November...".

PME is far from a loss making stock, with 36.6%PA earnings growth over 5 years.
But I suppose, if the market insists on lumping PME in with profitless growth dogs, it assumes PME must have fleas as well.

What sort of half year result are we expecting?.
This is what Sam Hupert said back on 18 Aug.

"In terms of maintaining the trend, we think we are off to a good start with the three large sites weimplemented towards the end of FY21 with Northwestern, NYU and Medstar contributing a full 12 monthsof revenue in FY22 which is material. On top of that we will also get transaction revenue from thoseopportunities we will be implementing in the first six months of this new financial year namely Intermountain, two of the five UC campuses and University of Vermont. So, whilst we don’t provideforecasts, we have told the market that we anticipate a step-up in transaction volumes in FY22."

And in the webcast, in respect to exam (transaction) revenue, Dr Hupert said the following:
"We are telling the market that we expect this growth to be a step change or a step growth in FY22..."

Cheers